Study of Purinostat Mesylate for Injection in the Treatment of Relapsed or Refractory B Cell-related Tumor-predominant

PHASE1CompletedINTERVENTIONAL
Enrollment

29

Participants

Timeline

Start Date

August 10, 2020

Primary Completion Date

September 7, 2022

Study Completion Date

March 29, 2024

Conditions
Diffuse Large B Cell Lymphoma,DLBCL
Interventions
DRUG

Purinostat Mesylate 1.2mg/m^2

1 case,The starting dose,Take the medicine once on D1, D8, D11, D15.

DRUG

Purinostat Mesylate 2.4mg/m^2

Take the medicine once on D1, D8, D11, D15.

DRUG

Purinostat Mesylate 4.0mg/m^2

Take the medicine once on D1, D8, D11, D15.

DRUG

Purinostat Mesylate 6.0mg/m^2

Take the medicine once on D1, D8, D11, D15.

DRUG

Purinostat Mesylate 8.4mg/m^2

Take the medicine once on D1, D8, D11, D15.

DRUG

Purinostat Mesylate 11.2mg/m^2

Take the medicine once on D1, D8, D11, D15.

DRUG

Purinostat Mesylate 15mg/m^2

Take the medicine once on D1, D8, D11, D15.

Trial Locations (1)

610000

West China Hospital Sichuan University, Chengdu

All Listed Sponsors
lead

Chengdu Zenitar Biomedical Technology Co., Ltd

INDUSTRY